Attached files
| file | filename |
|---|---|
| EX-32.2 - EXHIBIT 32.2 SECTION 906 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123119_ex32z2.htm |
| EX-32.1 - EXHIBIT 32.1 SECTION 906 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123119_ex32z1.htm |
| EX-31.2 - EXHIBIT 31.2 SECTION 302 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123119_ex31z2.htm |
| EX-31.1 - EXHIBIT 31.1 SECTION 302 CERTIFICATION - AXIM BIOTECHNOLOGIES, INC. | f10k123119_ex31z1.htm |
| EX-10.8 - MAY 1, 2019, LICENSE AGREEMENT WITH CANCHEW BIOTECHNOLOGIES, LLC. - AXIM BIOTECHNOLOGIES, INC. | f10k123119_ex10z8.htm |
| 10-K - FORM 10-K ANNUAL REPORT - AXIM BIOTECHNOLOGIES, INC. | f10k123119_10k.htm |
EXHIBIT 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to incorporation by reference of our report dated May 14, 2020, with respect to the consolidated balance sheets of Axim Biotechnologies, Inc. as of December 31, 2019 and 2018, and the related consolidated statement of operations, statement of shareholders’ deficit and cash flows for the years in the two-year period ended December 31, 2019, which includes an explanatory paragraph regarding the substantial doubt about the Company’s ability to continue as a going concern, included in this Annual Report on Form 10-K of Axim Biotechnologies, Inc. (the “Company”). We hereby consent to the incorporation by reference of said report in the Registration Statements of Axim Biotechnologies, Inc. on Form S-3 (File No. 333-220155).
//s// RBSM LLP
New York, New York
May 14, 2020